Platelet Transfusion Refractoriness
ACERTP
Characterization of Anti-HLA I Antibodies Involved in Platelet Transfusion Refractoriness: Optimization of the Transfusion Management of Patients With Severe Thrombocytopenia
1 other identifier
observational
50
1 country
1
Brief Summary
Platelet Transfusion Refractoriness is one of the severe complications after multiple transfusions in patients with severe thrombopenia. Platelet Transfusion Refractoriness is characterized by inefficient transfusion and arise from allo-antibodies specific of platelets antigenes, mostly carried by HLA-I molecules.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Feb 2022
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
February 2, 2022
CompletedFirst Submitted
Initial submission to the registry
May 25, 2022
CompletedFirst Posted
Study publicly available on registry
June 1, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 8, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 8, 2023
CompletedJanuary 5, 2026
December 1, 2025
1.5 years
May 25, 2022
December 30, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
Research of predictive criteria of Platelet transfusion refractoriness
Characterisation of anti-HLA I antibodies (recognised epitopes and isotypes) associated to Platelet transfusion refractoriness
blood samples before the transfusion of each chemotherapy cycle
Study Arms (2)
Patients with Platelet Transfusion Refractoriness
Patients without Platelet Transfusion Refractoriness
Interventions
platelet transfusion realised for Hematopoietic stem cells graft or for acute leukemia
Eligibility Criteria
Adult patient : * with Hematopoietic stem cells graft (autograft or allograft) * or with acute leukemia with the indication of platelet transfusion.
You may qualify if:
- Adult patient with Hematopoietic stem cells graft (autograft or allograft) or with acute leukemia with the indication of platelet transfusion.
You may not qualify if:
- Patient under guardianship
- Minor patient
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institut de cancérologie Strasbourg Europe
Strasbourg, France
Related Publications (1)
Couvidou A, Wald M, Angenieux C, Pires-Marafon J, Apithy MJ, Humbrecht C, Fornecker LM, Congy-Jolivet N, Dupuis A, Rollin J, Maitre B. Anti-HLA class I IgG subclasses skew platelet activation mechanisms in transfusion refractoriness. Haematologica. 2026 Feb 1;111(2):535-545. doi: 10.3324/haematol.2025.287677. Epub 2025 Sep 18.
PMID: 40963382DERIVED
Biospecimen
Blood samples
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Luc FORNECKER
Institut de cancérologie Strasbourg Europe
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 25, 2022
First Posted
June 1, 2022
Study Start
February 2, 2022
Primary Completion
August 8, 2023
Study Completion
August 8, 2023
Last Updated
January 5, 2026
Record last verified: 2025-12